Trial reportComprehensive psychiatry2023
Views about neuromodulation interventions for depression by stakeholder group, treatment modality, and depression severity.
Trial report in Comprehensive psychiatry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Barriers and facilitators to implementing deep brain stimulation for psychiatric disorders: a systematic review.Translational psychiatry · 2026Pooled it
- The differential effects of psychiatrists' and patients' prior experiences on views about psychiatric electroceutical interventions.Journal of psychiatric research · 2024Trial
- Mental Health Parity in Interventional Psychiatry: Access, Ethical and Policy Implications.Current psychiatry reports · 2026Review
- Public Perceptions of Neurotechnologies Used to Target Mood, Memory, and Motor Symptoms.Device · 2025Article
- Four dimensions of individualization in brain stimulation for psychiatric disorders: context, target, dose, and timing.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2025Review
- Is the Treatment Worse than the Disease?: Key Stakeholders' Views about the Use of Psychiatric Electroceutical Interventions for Treatment-Resistant Depression.Neuroethics · 2025Article
- Explaining key stakeholders' preferences for potential policies governing psychiatric electroceutical intervention use.Npj mental health research · 2024Article
- Opinion, Use and Knowledge About Transcranial Magnetic Stimulation in Spain: A National Survey of Mental Health Professionals.The Psychiatric quarterly · 2024Article
- Rewriting the Script: The Need for Effective Education to Address Racial Disparities in Transcranial Magnetic Stimulation Uptake in BIPOC Communities.Neuroethics · 2024Article
- Guideline-based care for psychiatric electroceuticals: Results from a National Survey of Board-Certified Psychiatrists.Journal of evaluation in clinical practice · 2024Article
- Looking through the lens of stigma: Understanding and anticipating concerns about the responsible development and use of psychiatric electroceutical interventions (PEIs).SSM. Mental health · 2023Article
- The influence of prior awareness on views about psychiatric electroceutical interventions among non-clinician stakeholders.Npj mental health research · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundThe past few decades have seen the emergence both of new neuromodulation treatment protocols and novel applications of standard neuromodulation interventions in psychiatry. Yet little is known about different stakeholders' views about these interventions.
methodsWe administered an online survey with an embedded video vignette experiment to four national samples: the general public (N = 1022), caregivers for people with depression (N = 1026), patients living with depression (N = 1050), and board-certified psychiatrists (N = 505). We randomly assigned subjects to one of eight conditions in our full factorial design: four neuromodulation interventions [electroconvulsive therapy, repetitive transcranial magnetic stimulation, deep brain stimulation, or adaptive brain implants] by two depression severity levels [moderate or severe]. In this paper we present results from ANOVA and linear regression models explaining how views about these four neuromodulation interventions-as measured in five attitudinal scales (general affect, perceived influence on self, perceived benefit, perceived risk, and perceived invasiveness)-vary by (1) intervention, (2) depression severity, and/or (3) stakeholder group.
resultsOur results provide evidence that psychiatrists views differ significantly in important ways from other stakeholder groups. Type of intervention also shaped participants' attitudes, including perceptions of invasiveness, effectiveness, and safety.
conclusionsGiven the differing affective valence among stakeholders and the differences found by modality and stakeholder groups across the different scales, future targeted educational initiatives could be developed to help address key misunderstandings and misinformed perceptions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.